Delcath Systems Secures “Buy” Rating with Ambitious Price Target

Delcath Systems (NASDAQ:DCTH) has received a renewed “buy” rating from HC Wainwright, as noted in a report released to investors on October 21, 2023. The firm set a price target of $30.00 for the stock, suggesting a significant upside of 187.22% from its previous closing price. This optimistic outlook contrasts with mixed assessments from other analysts in recent weeks.

Several brokerage firms have expressed varying opinions on Delcath Systems. Wall Street Zen downgraded the stock from “buy” to “hold” on October 12, while Canaccord Genuity Group reaffirmed its “buy” rating, maintaining a price target of $21.00. Conversely, Weiss Ratings issued a “sell (d+)” rating on December 29, and BTIG Research reiterated a “buy” stance with a target price of $23.00. Craig Hallum also maintained a “buy” rating, issuing a price target of $20.00. Currently, five equity research analysts rate the stock as a buy, while one holds a sell rating.

According to MarketBeat.com, the average rating for Delcath Systems stands at “Moderate Buy,” with a consensus price target of $22.40.

Latest Earnings and Stock Performance

Delcath Systems announced its latest quarterly earnings on November 4, 2023. The company reported earnings per share (EPS) of $0.02, aligning with analysts’ expectations. Despite this, the firm’s revenue for the quarter was $20.56 million, falling short of forecasts which estimated $23.22 million. Delcath Systems recorded a net margin of 1.50% and a return on equity of 7.02%.

Looking ahead, analysts predict that Delcath Systems will report an EPS of -0.79 for the current fiscal year. Additionally, on November 20, 2023, the company’s board approved a stock buyback program, allowing for the repurchase of up to $25.00 million in shares, which represents approximately 8.6% of its stock. Such buyback initiatives typically indicate that a company believes its shares are undervalued.

Insider Transactions and Institutional Holdings

In related news, CEO Gerard J. Michel acquired 11,500 shares of Delcath Systems on November 11 for an average price of $8.53 per share, totaling $98,095.00. Following this transaction, Michel owns 330,834 shares, valued at approximately $2,822,014.02, reflecting a 3.60% increase in his ownership stake. This acquisition was disclosed in a filing with the Securities and Exchange Commission.

Insiders currently hold 17.40% of Delcath Systems’ stock. Institutional investors have also made significant adjustments to their holdings. For instance, Rosalind Advisors Inc. increased its stake by 13.8% in the second quarter, owning 3,300,389 shares valued at $44,885,000 after acquiring an additional 400,000 shares.

Vanguard Group Inc. raised its ownership by 2.9% during the third quarter, now holding 1,657,428 shares worth $17,817,000. Geode Capital Management LLC significantly boosted its holdings by 128.1%, acquiring 394,902 shares in the same period. Other notable institutional investors include Nantahala Capital Management LLC and Marshall Wace LLP, which established new stakes valued at $7,164,000 and $6,572,000, respectively.

Overall, institutional investors and hedge funds collectively own 61.12% of Delcath Systems, highlighting strong institutional interest in the firm.

Delcath Systems is recognized as a specialty pharmaceutical and medical technology company focused on the development of its proprietary Hepatic CHEMOSAT® Delivery System. This innovative system aims to deliver high doses of chemotherapy directly to the liver, minimizing systemic exposure, particularly for patients with primary and metastatic liver tumors. The company’s technology allows oncologists to administer concentrated melphalan, targeting tumors effectively.

With the stock’s recent performance and the mixed outlook from analysts, Delcath Systems remains a focal point for investors keeping a close watch on developments in the specialty pharmaceuticals sector.